Turnstone Biologics to Present at Jefferies 2018 Global Healthcare Conference

NEW YORK & OTTAWA, Ontario--()--Turnstone Biologics, a clinical-stage immuno-oncology company developing the next-generation of oncolytic viral therapies, today announced that Sammy Farah, Ph.D., President and Chief Executive Officer, will present at the Jefferies 2018 Global Healthcare Conference on Wednesday, June 6, 2018 at 9:00 am Eastern Time in New York, NY.

About Turnstone Biologics

Turnstone Biologics is a clinical-stage, immuno-oncology company developing the next-generation of oncolytic viral immunotherapies for patients with a broad range of solid tumors. The company's Maraba (MG1) oncolytic virus platform is the first to combine the tumor-killing effects of an oncolytic virus with a tumor-targeted T-cell vaccine to harness an individual's own immune system to attack the tumor, with the goal of preventing recurrence and delivering a cure. Turnstone is advancing a robust pipeline of early-stage investigational therapies, including MG1-MAGEA3, targeting MAGE-A3 positive solid tumors such as non-small cell lung cancer (NSCLC), which is currently in Phase I/II clinical development as a monotherapy and in combination with a checkpoint inhibitor. Turnstone’s MG1-HPV therapy, targeting HPV positive cancers such as cervical and oropharyngeal cancer, is also entering clinical development after recently receiving U.S. FDA clearance of its IND. Turnstone’s lead investors include Versant Ventures, OrbiMed, F-Prime Capital Partners and FACIT. For more information, please visit http://turnstonebio.com/.

Contacts

Turnstone Biologics
Elliot Fox, 212-257-6724
efox@w2ogroup.com

Recent Stories

RSS feed for Turnstone Biologics